| Summary: | Wound treatment remains one of the most prevalent and economically burdensome healthcare concerns, often complicated by prolonged inflammation and bacterial infection, contributing to morbidity and mortality. Agents commonly used to treat chronic wound infections are limited due to their toxicity, multifactorial etiology of chronic wounds, deep skin infections, lack of sustained controlled delivery of drugs, and development of drug resistance. LL37 is an endogenous host defense peptide that has been shown to exhibit antimicrobial activity and is involved in the modulation of wound healing. Serpin A1 (A1) is a neutrophil elastase inhibitor and has been shown to demonstrate wound-healing property. Hence, our goal was to develop a topical combination nanomedicine for the controlled sustained delivery of LL37 and A1 that at precise combination ratios will significantly promote wound closure, reduce bacterial contamination, and enhance anti-inflammatory activity. We have successfully developed a solid lipid nanoparticle (SLN) formulation that can simultaneously deliver LL37 and A1 at specific ratios resulting in accelerated wound healing by promoting wound closure in BJ fibroblast cells and keratinocytes as well as synergistic enhancement of antibacterial activity against S. aureus and E. coli in comparison to LL37 or A1 alone. === May 2016
|
|---|
